News
Continued progress, with a strong order book - Q3 initial
Maria Karlsson Osipova
2026-11-20
07:54 CET
Q3 sales of SEK103m were largely in line with our forecast (-2%) and EBITDA of SEK18m was 13% above our estimate. The order book reached 235 systems, providing strong support for our estimates beyond Q4 2026. However, the gross margin of 62% was c400bp below our 66% forecast and the EBITDA beat rested on a cost base below our assumption but included a cSEK4m of capitalised, previously expensed CIPN development costs. If we exclude that item, EBITDA was cSEK15m (growth of c81% versus Q3 2025).
IBBM still going strong. Group sales grew 18% Y/Y, with Paxman US up 48% and IBBM caps (including both legacy Paxman and Dignitana) up 130% Y/Y, and IBBM locations up 19% Q/Q after an exceptionally strong Q2. The slight sequential dip of c2% Q/Q reflects softer UK external sales and self-pay erosion as sites switch; we do not interpret the slight sequential decline as evidence of weaker underlying demand. On the contrary, the order book of 235 systems was exceptionally strong, which provides support for our estimates beyond Q4 2026.
As for CIPN, commercialisation has started in the UK, with the first installations expected in December. We continue to expect the US De Novo pathway to support a commercial launch around Q2–Q3 2027 and include no material CIPN revenue in our forecasts.
Overall, we view Q3 as encouraging. Sales were largely in line with our estimates, while continued IBBM progress and the strong order book support our view on growth. Reported EBITDA was above of our forecast, although capitalised CIPN costs reduced the quality of the beat. We would expect a mildly positive share price reaction, but the gross margin miss and underlying EBITDA shortfall may limit the upside potential.
Earnings call interview will be published at 09:00 CET on DNB Carnegie’s YouTube channel, link here: https://www.youtube.com/@DNBCarnegiePlay